Exosome & Extracellular Vesicle (EV) Platform for CAR Delivery

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite notable progress, CAR-based immunotherapies remain constrained by suboptimal biodistribution, on-target/off-tumor adverse effects, transient persistence of engineered lymphocytes, and substantial bottlenecks in large-scale manufacturing that hinder equitable accessibility. To address these limitations, our Exosome & Extracellular Vesicle (EV) Delivery Platforms employ biologically derived, lipid-based nanocarriers engineered as adaptable vehicles for precise CAR molecule transport. Our portfolio encompasses end-to-end capabilities, including customized EV surface engineering, efficient effector molecule packaging, reproducible upscaling, and stringent analytical validation.

Introduction

Extracellular vesicles (EVs), a heterogeneous family of membrane-bound nanoparticles, encompass exosomes alongside microvesicles and apoptotic bodies, collectively serving as pivotal mediators of intercellular communication. These vesicles are characterized by their capacity to shuttle bioactive cargos including proteins, lipids, and nucleic acids in a cell-type-specific and context-dependent manner, thereby modulating recipient cell functions via surface ligand–receptor interactions, fusion-mediated cytosolic delivery, or horizontal gene transfer, all while maintaining remarkable stability in biological fluids. EVs have emerged as transformative tools, not only as delivery vehicles for CAR-encoding mRNA or cytotoxic payloads to redirect immune effector functions against tumor antigens, but also as "cell-free CARs" that bypass the safety concerns of live-cell therapies.

Fig.1 The classification, contents, and therapeutic promise of extracellular vesicles. (OA Literature) Fig.1 Extracellular vesicles: their subtypes, molecular payload, and clinical potential. ¹

Our Service

Our advanced Exosome & EV Platform for CAR Delivery offers a cutting-edge, cell-free alternative to traditional cell therapies. By engineering nanoscale vesicles to express CARs, our platform delivers precise, targeted cytotoxicity against solid tumors with superior tissue penetration and negligible risk of cytokine storms.

What We Can Offer

Our comprehensive platform offers end-to-end solutions for CAR-EV development, integrating advanced surface display engineering, high-efficiency cargo loading technologies, and optimized donor cell sourcing to deliver scalable, next-generation cell-free immunotherapies and targeted gene delivery vehicles.

Featured services of exosome and EV platforms for CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Donor cells.
CAR plasmids / Lentiviral vectors.

Key Steps:

Workflow of exosome and EV platforms for CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

High-purity CAR-EV / CAR-exosome concentrates.
CAR-EV functional validation data.

Key Advantages

Superior Biocompatibility & Negligible Immunogenicity: Leveraging endogenous-like membranes enriched with "don't eat me" signals, our platform evades immune clearance and eliminates the risk of Graft-versus-Host Disease (GvHD), enabling safer "off-the-shelf" allogeneic applications.
Exceptional Safety Profile with Low Toxicity Risks: As non-replicating, non-living nano-vesicles delivering protein or RNA cargoes rather than integrating viral vectors, CAR-EVs significantly mitigate the risks of Cytokine Release Syndrome (CRS), neurotoxicity (ICANS), and insertional mutagenesis.
Advanced Tissue Penetration & Precise Tumor Homings: Utilizing a natural nanoscale size, our CAR-EVs readily traverse complex physiological barriers including the blood-brain barrier (BBB), while exploiting synergistic CAR-mediated targeting and innate tumor-homing capabilities to accumulate precisely within solid tumors.

FAQ

Q1: How do you ensure the orientation and stability of CAR proteins on the EV membrane?

A1: We utilize advanced genetic engineering to fuse the CAR sequence with specific vesicle-associated scaffold proteins. This fusion design guarantees that the active antigen-binding domain (scFv) of the CAR is correctly displayed on the outer surface of the EV membrane, maintaining its targeting capability and stability.

Q2: Can CAR-EVs cross the Blood-Brain Barrier (BBB) for intracranial tumors?

A2: Yes. Unlike large, intact CAR-T cells, CAR-EVs have a natural nanoscale size and inherent biological properties that allow them to cross the blood-brain barrier. This makes our platform highly promising for treating brain malignancies such as glioblastoma (GBM).

Why Choose Us?

Choose our cutting-edge Exosome & EV platform for unprecedented CAR delivery. We offer clinical-grade, engineered extracellular vesicles that ensure superior biocompatibility, minimal immunogenicity, and enhanced safety without CRS or mutagenic risks. With advanced BBB penetration and dual-cargo capacity, we provide scalable, high-purity "off-the-shelf" solutions to revolutionize your solid tumor immunotherapies.

Customer Reviews

"Targeting solid tumors, especially glioblastoma, requires a delivery vehicle that can penetrate the BBB and survive the immunosuppressive tumor microenvironment. This engineered EV platform provided us with highly customized, donor-derived exosomes expressing anti-EGFRvIII CARs. These targeted EVs penetrated dense tissues far better than whole cells and successfully delivered their payload, showing outstanding therapeutic efficacy in our preclinical brain tumor models." Dr. S* L*.

"The biggest hurdle in traditional CAR-T is patient-specific, complex, and costly manufacturing. By using this EV Platform for CAR Delivery, we were able to explore a truly scalable 'off-the-shelf' therapeutic. Their platform produces clinical-grade, MSC-derived EVs with highly consistent CAR expression and uniform particle size distribution." M* V*, PharmD

How to contact us?

Accelerate your cell therapy discovery by connecting with our immunotherapy specialists. We invite you to explore how our cutting-edge CAR-EV technology can advance your next-generation therapeutic candidates. Connect with us today to initiate a technical assessment and receive a tailored budgetary proposal for your project.

Reference

Ng, Chiew Yong et al. "Scalable Production of Extracellular Vesicles and Its Therapeutic Values: A Review." International journal of molecular sciences vol. 23,14 7986. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms23147986.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.